PM
GBT

Parametrica Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Parametrica Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,275
Closed -$850K – 128
2021
Q2 		$850K Buy
24,275
+253
+1% +$9.88K 0.63% 41
2021
Q1 		$979K Buy
+24,022
New +$1.1M 0.47% 47
2017
Q3 		– Sell
-21,566
Closed -$590K – 455
2017
Q2 		$590K Buy
+21,566
New +$642K 0.55% 21

Other funds holding GBT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Parametrica Management's GBT Position: Q3 2021 in Review

Parametrica Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2021, closing a stake of 24,275 shares — an estimated $850K sold.

Parametrica Management first reported a position in GBT in Q2 2017 and held it in 3 quarters. The position peaked at $979K in Q1 2021. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

  • Parametrica Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
  • Parametrica Management sold 24,275 Global Blood Therapeutics, Inc. shares in Q3 2021, an estimated $850K.
  • Parametrica Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
  • Parametrica Management's Global Blood Therapeutics, Inc. position peaked at $979K in Q1 2021.
  • 187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on Parametrica Management's 13F filing for Q3 2021, filed 12 Nov 2021.